2 Beaten-Down Stocks That Still Aren't Worth Buying

The article flags Recursion Pharmaceuticals (RXRX) as an AI-driven drug discovery platform that still lacks any marketed product and faces ongoing clinical/regulatory risk, making it an unattractive “falling knife” despite early pipeline signals (e.g., REC-4881 polyp-burden reductions). For Sarepta Therapeutics (SRPT), it highlights Elevidys safety setbacks (two Elevidys patients died from acute liver failure) and a boxed warning, with risk hinging on whether sirolimus pre/post-dosing can mitigate acute liver injury/failure in non-ambulatory DMD patients while defending market share as competitors enter.

Analysis

RXRX and SRPT are being valued less on pipeline probability than on credibility and financing optionality. For RXRX, the market is effectively asking whether the platform can produce a single late-stage de-risking event before the cash burn forces another capital raise; absent that, the AI narrative stays a multiple story, not an earnings story, and small-cap biotech multiples usually compress fastest when the “platform” claim remains unproven.

SRPT is a different kind of fragility: concentration risk. Even if the safety workarounds help, the core asset is still vulnerable to share loss as alternative DMD modalities mature, so the franchise could go from monopoly-like economics to a shrinking, lower-margin installed base over 12-18 months. The near-term catalyst is binary clinical/regulatory execution; the medium-term risk is that incremental label clarity is mistaken for durable franchise repair.

The contrarian point is that both names can rally violently on any credible de-risking data, so the right trade is timing, not conviction. Consensus may be overestimating how much “good enough” safety data can restore SRPT’s terminal value, while underestimating how much RXRX needs one real clinical win to change funding perceptions. In both cases, the key falsifier is a durable data or approval surprise that changes cash-flow visibility, not headline sentiment.

Key Decisions for Investors

• Short SRPT into strength on a 1-3 month horizon via put spreads or a small equity short; the risk/reward favors downside if safety mitigation data are inconclusive. Cover if new data materially reduce liver-injury incidence or the FDA signals label expansion.
• Pair trade: long XBI / short RXRX for 3-6 months. This isolates idiosyncratic execution risk versus broad biotech beta; thesis fails if RXRX delivers a credible late-stage readout or strategic partner that de-risks dilution.
• Do not add fresh long exposure to either name ahead of binary data; wait for post-event pricing. The better entry is after a reflexive selloff only if the balance sheet still provides >12 months runway and the readout is clearly survivable.
• Monitor RXRX financing risk as the key watch item: if cash burn implies a raise before a material efficacy readout, expect another 20-30% multiple reset even without negative science.